{"id":"gamevac-combi-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated tick-borne encephalitis virus and Borrelia burgdorferi (Lyme disease) antigens that trigger both humoral and cellular immune responses. This dual-antigen approach provides protection against the two most common tick-borne infections in Eastern Europe and Russia.","oneSentence":"GamEvac-Combi is a combination vaccine that stimulates immune responses against tick-borne encephalitis and Lyme disease through viral antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:31:02.448Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of tick-borne encephalitis"},{"name":"Prevention of Lyme disease (Borreliosis)"}]},"trialDetails":[{"nctId":"NCT03072030","phase":"PHASE4","title":"International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2017-08-03","conditions":"Ebola Virus Disease, Prevention","enrollment":2000},{"nctId":"NCT02911415","phase":"","title":"Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi","status":"COMPLETED","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2016-10","conditions":"Ebola Hemorrhagic Fever","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"GamEvac-Combi (vaccine)","genericName":"GamEvac-Combi (vaccine)","companyName":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","companyId":"gamaleya-research-institute-of-epidemiology-and-microbiology-health-ministry-of","modality":"Biologic","firstApprovalDate":"","aiSummary":"GamEvac-Combi is a combination vaccine that stimulates immune responses against tick-borne encephalitis and Lyme disease through viral antigens. Used for Prevention of tick-borne encephalitis, Prevention of Lyme disease (Borreliosis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}